Fund profile

Abingorwth

United Kingdom

Leading

About

Abingworth, founded in 1973, is a transatlantic life sciences investment firm with a robust portfolio and a strategic focus on turning innovative science into transformative medical treatments. With offices in London, Boston, and San Francisco, Abingworth has invested in over 179 companies, resulting in 73 IPOs and 46 M&As. The firm operates across three main investment stages: seed and early-stage, development stage, and clinical co-development, and typically invests between $500,000 to $2 million in initial rounds, supporting portfolio companies through subsequent funding stages. Notable investments include Adaptate Biotherapeutics, Jasper, and Tizona Therapeutics. Abingworth's team, led by Managing Partners Tim Haines and Kurt von Emster, brings decades of experience in life sciences and venture capital. The firm is deeply embedded in key biotech hubs, facilitating productive interactions with entrepreneurs and access to top-tier scientific talent. The firm emphasizes long-term partnerships, providing not just capital but also strategic guidance in areas such as clinical development, regulatory approval, and commercialization. Abingworth's recent integration with Carlyle Group underscores its commitment to expanding its impact in the global healthcare investment ecosystem. Startups seeking investment from Abingworth should have groundbreaking science with the potential to materially improve patient outcomes. The firm values deep industry expertise, strong leadership, and a clear path to transformative impact.

Details

Average check

$10M-$50M

Round

Series ASeries BSeries C+

Geo focus

Highlights

$5.1M

Historical average check

$210M

Historical max check

February 2025

Last investment date

185

Investments

AI & Deep Tech

Software & Apps

Healthtech & Wellness

Biotech

Pharma

Legal & Professional services

Hardware. Robotics & IoT

Other

Funds that also invest in Biotech